FDA Introduces New Guidance to Streamline Biosimilar Development and Cut Drug Costs
The U.S. Food and Drug Administration (FDA) has announced new measures aimed at accelerating the development of biosimilar medicines and lowering the overall cost of biologic treatments in the United States.
















